ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Competing Risks to Transplant in Bridging With Continuous-Flow Left Ventricular Assist Devices

Friday, September 30, 2022

Submitted by

Cameron Lind

Source

Source Name: Annals of Thoracic Surgery

Source URL: https://doi.org/10.1016/j.athoracsur.2021.09.079

Author(s)

Nadia H. Bakir, BS; Michael J. Finnan, MS; Akinobu Itoh, MD, PhD; Michael K. Pasque, MD; Gregory A. Ewald, MD; Kunal D. Kotkar, MD; Ralph J. Damiano Jr., MD; Marc R. Moon, MD; Justin C. Hartupee, MD, PhD; Joel D. Schilling, MD, PhD; Muhammad F. Masood, MD

This retrospective review compares the outcomes of heart failure patients who used continuous-flow left ventricular device (CF-LVAD) support with patients listed as primary transplant candidates at the same center. The results showed that CF-LVAD patients had excellent outcomes regardless of how long they were on the waitlist. This change of risk should be taken into account when considering CF-LVAD support as a bridge to transplant.